Feb. 8 at 8:39 PM
$RGNX you can chase short pennies with Stevie Wonder, but don’t be fooled. RGX121 has always been a minor piece to their thesis (which will be approved eventually). One decent size BP player seems to know where the big opportunity is…
AbbVie’s
$ABBV Relationship with
$RGNX is a major strategic development partnership focused on a one‑time gene therapy for serious eye diseases: ABBV‑RGX‑314
• AbbVie brings global development and commercialization strength.
• REGENXBIO brings gene‑therapy technology and manufacturing expertise.
• The deal includes significant up‑front (
$370MM) AND potential milestone payments (
$1.38B), shared U.S. profits, and royalties on ex‑U.S. sales
This collaboration remains one of the key drivers of REGENXBIO’s clinical and financial strategy.
Assuming dosing milestones occur in 2026, REGENXBIO could receive up to
$200 million in AbbVie milestone payments this year
